It has been a rough period for a number of high-quality ASX 200 shares.
Some have sold off heavily on short-term concerns, even though their longer-term outlooks still look intact. When that happens, I think it is worth taking a closer look.
Here are three that stand out to me right now.
Image source: Getty Images
Cochlear Ltd (ASX: COH)
Cochlear shares have fallen sharply this week after cutting its FY26 earnings guidance, and that has clearly shaken investor confidence.
The cochlear implant company now expects underlying net profit after tax of $290 million to $330 million, well below previous expectations. Softer demand in developed markets, weaker referral activity, and some uncertainty tied to the Middle East have all played a role.
That sounds concerning, but I think the context matters.
A lot of the weakness appears to be short term. Hospital capacity constraints, lower consumer confidence, and delays in referrals are affecting surgical volumes right now. I don't believe these are structural changes to the business.
At the same time, Cochlear is still seeing strong adoption of its new Nexa system and continues to gain market share in developed markets. Services revenue is also growing strongly, with double-digit growth in the third quarter.
What I think is important is that the long-term opportunity has not changed. The adult and seniors segment continues to represent a large growth market, and Cochlear is continuing to invest in new technology and expand its pipeline.
For me, this looks like a period of short-term pressure rather than a broken growth story.
Treasury Wine Estates Ltd (ASX: TWE)
Treasury Wine Estates is another name that has been under pressure, with this ASX 200 share down heavily over the past year.
However, its update this week suggests things may be starting to turn.
The company is rolling out a new regional operating model aimed at improving execution and efficiency across its global business. This is part of a broader transformation strategy focused on long-term growth.
At the same time, underlying demand trends appear to be improving.
Depletions, which are a key measure of sales momentum, returned to growth in several markets. In the US, depletions were up 9.1% in the third quarter, while China delivered particularly strong growth during the Chinese New Year period.
Management also expects earnings in the second half to be higher than the first half.
To me, this combination of improving momentum and structural change could be important. If execution continues to improve, sentiment could start to follow.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix Pharmaceuticals has also seen its share price fall significantly, largely due to delays around regulatory approvals.
That said, there has been some meaningful progress recently. The FDA has now accepted Telix's application for its TLX101-Px imaging agent, with a decision expected in September 2026. This moves the product closer to potential commercialisation.
The product targets glioma imaging, an area with a significant unmet need, and has received both Fast Track and Orphan Drug designations.
Beyond this, the broader pipeline continues to develop, with multiple late-stage assets and ongoing investment supporting future growth.
I think this is one where progress can be uneven, but the long-term opportunity is still there.
Foolish takeaway
These three ASX 200 shares have all fallen heavily, but for different reasons.
Cochlear is dealing with softer near-term demand, Treasury Wine Estates is reshaping its business, and Telix is working through regulatory timelines.
In each case, I think the long-term story still looks intact. That is why I see these as three ASX 200 shares that could be worth a closer look after their recent sell-offs.
